Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlot...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Sathornsumetee, Sith, Desjardins, Annick, Vredenburgh, James J., McLendon, Roger E., Marcello, Jennifer, Herndon, James E., Mathe, Alyssa, Hamilton, Marta, Rich, Jeremy N., Norfleet, Julie A., Gururangan, Sridharan, Friedman, Henry S., Reardon, David A.
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2010
Fag:
Clinical Investigations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018944/
https://ncbi.nlm.nih.gov/pubmed/20716591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq099
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker